RIL
NPCE icon

Rothschild Investment LLC’s Neuropace NPCE Stock Holding History

Rothschild Investment LLC’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445 Buy
28
+14
+100% +$225 ﹤0.01% 3288
2026
Q1 		$184 Buy
+14
New +$210 ﹤0.01% 3319

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Rothschild Investment LLC's NPCE Position: Q2 2026 in Review

Rothschild Investment LLC increased its Neuropace (NPCE) stake by 100% in Q2 2026, buying an estimated $225 and bringing the position to 28 shares worth $445. The position accounts for ﹤0.01% of the portfolio, ranked #3288.

Rothschild Investment LLC first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Rothschild Investment LLC held 28 shares of Neuropace worth $445 as of Q2 2026.
  • Rothschild Investment LLC bought 14 Neuropace shares in Q2 2026, an estimated $225.
  • Neuropace made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3288 holding.
  • Rothschild Investment LLC first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.